Bayer's Menopause Drug Elinzanetant Met Primary Endpoints in Phase 3 Studies
By Pierre Bertrand
Bayer said that its menopause drug Elinzanetant met the primary endpoints of its Oasis 1 and 2 Phase 3 studies.
When compared with placebo, the drug showed a statistically significant reduction in the frequency and the severity of moderate to severe vasomotor symptoms, also known as hot flashes.
It also demonstrated statistically significant improvements in sleep disturbances and menopause-related quality of life, the company said.
The Oasis 1 and 2 studies assessed the efficacy and safety of Elinzanetant when administered orally once daily. The result of the Oasis 3 Phase 3 study is expected in the coming months, Bayer said.
The company added that it plans to submit the data from the Oasis studies to health authorities for marketing authorizations.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
January 08, 2024 02:50 ET (07:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?